CTLA4 and cancer: Immune checkpoint molecules, such as CTLA-4 and PD-1, play critical roles in regulating immune responses and suppressing immune effector cells, thus leading to the development of ICIs, which have proven to be exceptionally effective in some cancers in some patients [174].